Cerevel Therapeutics Hldg Inc (NQ: CERE )
32.60 +0.06 (+0.18%) Streaming Delayed Price Updated: 4:00 PM EDT, May 31, 2023 Add to My Watchlist
All News about Cerevel Therapeutics Hldg Inc
Cerevel Therapeutics Hldg: Q1 Earnings Insights
May 03, 2023
Where Cerevel Therapeutics Hldg Stands With Analysts
April 03, 2023
Analyst Expectations for Cerevel Therapeutics Hldg's Future
March 09, 2023
Why Reata Pharmaceuticals Shares Are Trading Higher By 140%; Here Are 20 Stocks Moving Premarket
March 01, 2023
Gainers Reata Pharmaceuticals Inc (NASDAQ: RETA) rose 140.8% to $75.06 in pre-market trading after the company reported the FDA approval of SKYCLARYS for patients with Friedreich's Ataxia.
What 8 Analyst Ratings Have To Say About Cerevel Therapeutics Hldg
December 06, 2022
Benzinga's Top Ratings Upgrades, Downgrades For February 23, 2023
February 23, 2023
Why Quoin Pharmaceuticals Shares Are Trading Lower By Over 40%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
February 22, 2023
Gainers Windtree Therapeutics Inc (NASDAQ: WINT) shares jumped 75.3% to $0.2921. Windtree Therapeutics has been granted U.S. patent number 11,583,540 titled "Istaroxime-Containing Intravenous...
Analyst Views Karuna Therapeutics' New Licensing Deal 'As Intriguing'
February 03, 2023
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
December 19, 2022
Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
November 01, 2022
Benzinga's Top Ratings Upgrades, Downgrades For October 20, 2022
October 20, 2022
Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2022
September 29, 2022
Benzinga's Top Ratings Upgrades, Downgrades For September 26, 2022
September 26, 2022
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following